Immunomodulating fusion protein (CT001) to treat solid malignancies

Cura Therapeutics is developing innovative immunotherapies to cure solid malignancies and infectious diseases. Cura Therapeutics immunotherapy platform simultaneously activates the immune response against cancer while disrupting the tumor blood supply. These immunotherapies also induce an immunological memory that prevent cancer recurrence. Currently, there are no treatments on the market or in clinical trials that combine these properties in one single therapy. The objective of this project is to complete the preclinical stage of Cura Therapeutics’ lead immunotherapy (CT001, aka human FIST). The pre-clinical stage includes in vitro experiments to characterize Cura Therapeutics immunotherapies (CT001 variants) and in vivo experiments to determine Pk, Pd, MTD and efficacy studies in combination with immune checkpoint inhibitors in four mouse models of cancer (pancreatic cancer, colorectal cancer, breast cancer and melanoma).The goal is to build a pipeline that targets a broad range of solid malignancies that can be used as a standalone treatment or as combination therapies with CAR-T, Immune checkpoint inhibitors (ICI), or chemotherapy. The collaboration with Dr. Michel L. Tremblay lab will generate the data necessary to advance to IND-enabling studies.

Faculty Supervisor:

Michel Tremblay

Student:

Partner:

Cura Therapeutics

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

McGill University

Program: